Anti-cancer immunotherapies targeting the programmed cell death/-ligand 1(PD-1/PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), commonly spoken as immune checkpoint inhibitors (ICIs), have proven to be effective in many tumors (139). This evidence concerns the gene CD274 and cancer.